Back to search results

Study of PD-32766D/T for Clear Cell Renal Cell Carcinoma

This study is testing two related treatments, PD-32766D and PD-32766T, for people with clear cell renal cell carcinoma (a type of kidney cancer) that has returned or is difficult to treat. You would first receive an injection of PD-32766D and have a PET/CT scan to see if your tumor has a specific marker called Carbonic Anhydrase IX (CA9). If it does, you may then receive up to six cycles of PD-32766T, which is given intravenously (into a vein). This study aims to understand how safe PD-32766T is, how your body handles it, and if it shows any early signs of fighting the cancer. This is for adults aged 18 and older whose cancer has progressed after standard treatments.

Study design
This is an open-label, multi-center study with an estimated 60 participants. It is a Phase 1a/1b study, meaning it's an early-stage trial looking at safety and dosage.
What's involved
You would first have an IV injection of PD-32766D followed by a PET/CT scan. If eligible, you would then receive up to 6 cycles of PD-32766T intravenously, with safety monitored for about 6 months.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored through the completion of the study, which is an average of 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07688187

A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

Recruiting
PHASE1Ages 18+InterventionalTreatment
PeptiDream Inc.
~60 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:PD-32766D (a Copper-64 [64Cu] labeled peptide)PD-32766T (an Actinium-225 [225Ac] labeled peptide)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number and proportion of participants who experience at least 1 dose-limiting toxicities (DLTs).
Measured over Through completion of DLT evaluation (6weeks)
+3 more outcomes measured

Conditions

Clear Cell Renal Cell Carcinoma

Explore related trials

Clear Cell Renal Cell CarcinomaCarbonic Anhydrase 9

NCT07688187

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Research site

    Omaha, Nebraskano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Clinical Lead
[email protected]
044-270-1300
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histological confirmed locally advanced, unresectable, or metastatic ccRCC, after all available standard therapy.
Presence of evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) guideline (defined by RECIST v1.1). 3. Presence of positive tumor uptake 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1. 5. The participant's with adequate organ function 6. Life expectancy of at least 12 weeks as assessed by the Investigator.

What this trial measures

  • Number and proportion of participants who experience at least 1 dose-limiting toxicities (DLTs).Through completion of DLT evaluation (6weeks)

    Number of participants with DLT and DLT rate

  • Incidence, intensity, seriousness, and causality of adverse events (AEs), treatment-emergent adverse events (TEAEs), adverse event of special interest (AESI) and serious adverse events (SAEs).Through study completion, an average of 6 months.

    Number and proportion of participants with AEs, TEAEs, AESI and SAEs.

  • Incidence of TEAEs leading to dose delay, dose interruption, dose reduction, and/or discontinuation.Through study completion. an average of 6 months

    Number and proportion of participants with TEAEs leading to dose delay, dose interruption, dose reduction, and/or discontinuation as a measure of tolerability.

  • Maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of PD-32766T based on dose-limiting toxicities.Through completion of DLT evaluation (6weeks).

    MTD and RDE are determined based on the occurrence of DLTs during the DLT evaluation period.